SCHEMBL24931121

SCHEMBL24931121

CCOC(=O)c1cnn(CCNC(=O)OC(C)(C)C)c1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
IDO1 P14902 1/20 0.43
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
SIGMAR1 Q99720 2/20 0.42
CYP3A4 P08684 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30239588 0.89 CYP3A4 (0.47) IDO1SIGMAR1CYP3A4ADORA3ADORA2A
SCHEMBL18187542 0.84 IDO1 (0.43) IDO1CRHBPCRHR2SIGMAR1ADORA3
SCHEMBL16682537 0.79 SMN1; SMN2 (0.46) ALDH1A1IDO1CRHBPCRHR2SIGMAR1
SCHEMBL24931118 0.78 CRHBP (0.45) ALDH1A1IDO1CRHBPCRHR2SIGMAR1
SCHEMBL25310219 0.76 ALDH1A1 (0.52) ALDH1A1KMT2ASMN1; SMN2HPGD
SCHEMBL18833462 0.76 ADORA3 (0.41) ALDH1A1CYP3A4ADORA3ADORA2AKMT2A
SCHEMBL20140105 0.75 CKS1B (0.44) ALDH1A1IDO1SIGMAR1CYP3A4KMT2A
SCHEMBL31539458 0.74 NPC1 (0.50) ALDH1A1CYP3A4ADORA3ADORA2AKMT2A
SCHEMBL20140432 0.74 CKS1B (0.45) IDO1SIGMAR1CYP3A4SMN1; SMN2HDAC3
SCHEMBL16402387 0.74 ADORA3 (0.40) ALDH1A1CYP3A4ADORA3ADORA2AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 ALDH1A1 2692/4885IDO1 2454/4885CRHBP 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.